S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
NASDAQ:CBLI

Cleveland BioLabs Stock Forecast, Price & News

$3.55
-0.10 (-2.74 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.49
Now: $3.55
$3.74
50-Day Range
$2.71
MA: $3.30
$3.94
52-Week Range
$0.80
Now: $3.55
$5.43
Volume252,024 shs
Average Volume230,720 shs
Market Capitalization$47.34 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.
Cleveland BioLabs logo

MarketRank

Overall MarketRank

0.64 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBLI
CUSIPN/A
Phone716-849-6810
Employees7

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.11 million
Book Value$0.09 per share

Profitability

Net Income$-2,650,000.00
Net Margins-382.26%

Miscellaneous

Market Cap$47.34 million
Next Earnings DateN/A
OptionableNot Optionable
$3.55
-0.10 (-2.74 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

How has Cleveland BioLabs' stock been impacted by COVID-19 (Coronavirus)?

Cleveland BioLabs' stock was trading at $3.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CBLI stock has increased by 12.7% and is now trading at $3.55.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Cleveland BioLabs?

Wall Street analysts have given Cleveland BioLabs a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cleveland BioLabs wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) issued its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.16 million for the quarter. Cleveland BioLabs had a negative return on equity of 123.97% and a negative net margin of 382.26%.
View Cleveland BioLabs' earnings history
.

Who are some of Cleveland BioLabs' key competitors?

What other stocks do shareholders of Cleveland BioLabs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include iBio (IBIO), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Biocept (BIOC) and Co-Diagnostics (CODX).

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the following people:
  • Mr. Christopher Zosh, VP of Fin., Interim Principal Exec. Officer, Principal Financial Officer & Accounting Officer (Age 46, Pay $103.49k)
  • Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 65, Pay $66.14k)
  • Dr. Langdon L. Miller, Chief Medical Officer (Age 67, Pay $73.72k)

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How do I buy shares of Cleveland BioLabs?

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of CBLI stock can currently be purchased for approximately $3.55.

How big of a company is Cleveland BioLabs?

Cleveland BioLabs has a market capitalization of $47.34 million and generates $1.11 million in revenue each year. Cleveland BioLabs employs 7 workers across the globe.

What is Cleveland BioLabs' official website?

The official website for Cleveland BioLabs is www.cbiolabs.com.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.